Published in J Biol Response Mod on January 01, 1984
Influence of fine structure of lipid A on Limulus amebocyte lysate clotting and toxic activities. Infect Immun (1984) 1.89
Dissociation of lipopolysaccharide (LPS)-inducible gene expression in murine macrophages pretreated with smooth LPS versus monophosphoryl lipid A. Infect Immun (1993) 1.41
Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun (1990) 1.35
Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A. Infect Immun (1988) 1.31
Characteristics of bacterial lipopolysaccharide induction of interleukin 1 synthesis and secretion by human monocytes. Clin Exp Immunol (1986) 1.18
Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A. Sci Signal (2011) 1.03
Rhodopseudomonas sphaeroides lipid A derivatives block in vitro induction of tumor necrosis factor and endotoxin tolerance by smooth lipopolysaccharide and monophosphoryl lipid A. Infect Immun (1992) 1.01
Immunomodulatory activity of monophosphoryl lipid A in C3H/HeJ and C3H/HeSnJ mice. Infect Immun (1989) 1.00
Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis. J Clin Microbiol (1989) 1.00
Inactivation of suppressor T cell activity by the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides. Infect Immun (1990) 0.94
Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens. J Exp Med (1992) 0.93
Structural features that influence the ability of lipid A and its analogs to abolish expression of suppressor T cell activity. Infect Immun (1992) 0.92
SDZ MRL 953, a novel immunostimulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis. Antimicrob Agents Chemother (1991) 0.91
Enrichment of suppressor T cells by means of binding to monophosphoryl lipid A. Infect Immun (1990) 0.91
Molecular structures that influence the immunomodulatory properties of the lipid A and inner core region oligosaccharides of bacterial lipopolysaccharides. Infect Immun (1994) 0.88
Effects of Differences in Lipid A Structure on TLR4 Pro-Inflammatory Signaling and Inflammasome Activation. Front Immunol (2012) 0.88
Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A. Infect Immun (1993) 0.86
Myocardial protection after monophosphoryl lipid A: studies of delayed anti-ischaemic properties in rabbit heart. Br J Pharmacol (1996) 0.85
Adjuvant effects of trehalose dimycolate on the antibody response to type III pneumococcal polysaccharide. Infect Immun (1989) 0.83
Effect of monophosphoryl lipid A on host resistance to bacterial infection. Infect Immun (1986) 0.82
Triggering role of nitric oxide in the delayed protective effect of monophosphoryl lipid A in rat heart. Br J Pharmacol (1999) 0.81
Differential effects of monophosphoryl lipid A on expression of suppressor T cell activity in lipopolysaccharide-responsive and lipopolysaccharide-defective strains of C3H mice. Infect Immun (1991) 0.79
Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria. Infect Immun (2013) 0.79
Monophosphoryl lipid A provides biphasic cardioprotection against ischaemia-reperfusion injury in rat hearts. Br J Pharmacol (1999) 0.78
Monophosphoryl Lipid A: A Novel Agent for Inducing Pharmacologic Myocardial Preconditioning. J Thromb Thrombolysis (1996) 0.77
Alterations in frequency of interleukin-2 (IL-2)-, gamma interferon-, or IL-4-secreting splenocytes induced by Candida albicans mannan and/or monophosphoryl lipid A. Infect Immun (1998) 0.77
Anti-tumour activity of low-toxicity lipopolysaccharide of Bordetella pertussis. Br J Cancer (1994) 0.76
Marine compounds with therapeutic potential in gram-negative sepsis. Mar Drugs (2013) 0.76
Reaction of endotoxin and surfactants. I. Physical and biological properties of endotoxin treated with sodium deoxycholate. J Bacteriol (1966) 2.86
Preparation of cell walls and protoplasm of Neisseria with the Ribi cell fractionator. J Bacteriol (1969) 2.61
Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem (1982) 2.33
Physical aspects of reversible inactivation of endotoxin. Ann N Y Acad Sci (1966) 2.21
Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. Am Rev Respir Dis (1973) 2.18
Effects of oil-treated mycobacterial cell walls on the organs of mice. J Bacteriol (1967) 1.93
Influence of fine structure of lipid A on Limulus amebocyte lysate clotting and toxic activities. Infect Immun (1984) 1.89
Effective nonliving vaccine against experimental tuberculosis in mice. J Bacteriol (1966) 1.83
Separation of the mixture of trehalose 6,6'-dimycolates comprising the mycobacterial glycolipid fraction, "P3". Biochem Biophys Res Commun (1977) 1.82
Duration of immunity to tuberculosis in mice vaccinated intravenously with oil-treated cell walls of Mycobacterium bovis strain BCG. J Immunol (1967) 1.75
Factors influencing protection against experimental tuberculosis in mice by heat-stable cell wall vaccines. J Bacteriol (1966) 1.75
Separation and characterization of toxic and nontoxic forms of lipid A. Rev Infect Dis (1984) 1.71
Frequency of occurrence of native hapten among enterobacterial species. J Bacteriol (1966) 1.66
Biologically active components from mycobacterial cell walls. V. Granuloma formation in mouse lungs and guinea pig skin. Cell Immunol (1975) 1.65
Effectiveness of cell walls of Mycobacterium bovis strain BCG administered by various routes and in different adjuvants in protecting mice against airborne infection with Mycobacterium tuberculosis strain H37Rv. Am Rev Respir Dis (1969) 1.65
Chemical, biological, and structural properties of stable Proteus L forms and their parent bacteria. J Bacteriol (1967) 1.55
Alteration of physical, chemical, and biological properties of endotoxin by treatment with mild alkali. J Bacteriol (1969) 1.48
Immunotherapy of cancer: regression of established intradermal tumors after intralesional injection of mycobacterial cell walls attached to oil droplets. J Natl Cancer Inst (1974) 1.42
Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. J Biol Chem (1985) 1.37
Migration inhibitory factor and type II interferon in the circulation of mice sensitized with mycobacterial components. J Immunol (1975) 1.33
Physical structure of a native protoplasmic polysaccharide from Escherichia coli. J Immunol (1967) 1.32
Delayed hypersensitivity and granulomatous response after immunization with protein antigens associated with a mycobacterial glycolipid and oil droplets. J Immunol (1976) 1.31
Lipid A and immunotherapy. Rev Infect Dis (1984) 1.29
Hybrid formation between bacterial endotoxins. J Exp Med (1967) 1.26
Immunogenicity of cell walls from various mycobacteria against airborne tuberculosis in mice. J Bacteriol (1968) 1.25
Efficacy of mycobacterial cell walls as a vaccine against airborne tuberculosis in the Rheusus monkey. J Infect Dis (1971) 1.21
Biologically active components from mycobacterial cell walls. IV. Protection of mice against aerosol infection with virulent mycobacterium tuberculosis. Cell Immunol (1975) 1.20
Relationship of footpad sensitivity to purified protein derivatives and resistance to airborne infection with Mycobacterium tuberculosis of mice vaccinated with mycobacterial cell walls. J Bacteriol (1969) 1.14
Specificity of resistance to tuberculosis and to salmonellosis stimulated in mice by oil-treated cell walls. Proc Soc Exp Biol Med (1967) 1.14
Modification of selected host-reactive properties of endotoxin by treatment with sodium deoxycholate. J Bacteriol (1968) 1.12
Bacterial endotoxin selectively prevents the expression of scavenger-receptor activity on human monocyte-macrophages. J Immunol (1985) 1.09
Moieties of mycobacterial mycolates required for inducing granulomatous reactions. Cell Immunol (1978) 1.06
Isolation of a nontoxic lipid A fraction containing tumor regression activity. Cancer Res (1981) 1.01
Aerosol-Induced Tuberculosis in Subhuman Primates and the Course of the Disease After Intravenous BCG Vaccination. Infect Immun (1970) 0.99
Immunization of mice by combinations of inactive fractions of Mycobacterium bovis strain BCG. Proc Soc Exp Biol Med (1969) 0.99
Induction of resistance to tuberculosis in mice with defined components of mycobacteria and with some unrelated materials. Immunology (1982) 0.98
Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects. Int J Immunopharmacol (1986) 0.96
The adjuvant properties of a nontoxic monophosphoryl lipid A in hyporesponsive and aging mice. J Biol Response Mod (1987) 0.95
Cutaneous granulomatous response to BCG cell walls with reference to cancer immunotherapy. Infect Immun (1976) 0.94
Effects of mycobacterial fractions and muramyl dipeptide on the resistance of mice to aerogenic influenza virus infection. Int J Immunopharmacol (1983) 0.92
Reaction of endotoxin and surfactants. II. Immunologic properties of endotoxins treated with sodium deoxycholate. J Immunol (1968) 0.91
Studies of delayed reactions using protoplasm from acid-fast bacilli as provoking antigen. Am Rev Respir Dis (1966) 0.91
Cell walls from Mycobacterium tuberculosis (BCG) as vaccine against Mycobacterium leprae infections in mice. Proc Soc Exp Biol Med (1968) 0.89
Skin reactions in rabbits sensitized with typical and atypical mycobacteria and tested with homologous and heterologous protoplasm. Am Rev Respir Dis (1966) 0.88
Glycolipid induced proliferation of lipopolysaccharide hyporesponsive C3H/HeJ splenocytes. J Leukoc Biol (1988) 0.88
Characterization of a nontoxic monophosphoryl lipid A. Rev Infect Dis (1988) 0.87
Different structural requirements of endotoxic glycolipid for tumor regression and endotoxic activity. Biochem Biophys Res Commun (1982) 0.86
Microparticulate gel chromatography accelerated by centrifugal force and pressure. Methods Biochem Anal (1974) 0.86
Immunotherapy with nonviable microbial components. Ann N Y Acad Sci (1976) 0.86
Enhancement of macrophage-mediated tumor cell killing by bacterial outer membrane proteins (porins). Infect Immun (1983) 0.85
Eradication by immunization with mycobacterial vaccines and tumor cells of microscopic metastases remaining after surgery. Cancer Res (1979) 0.85
Trehalose dimycolate from various mycobacterial species induces differing anti-infectious activities in combination with muramyl dipeptide. Infect Immun (1985) 0.84
Structural requirements of endotoxic glycolipid for antitumor and toxic activity. J Biochem (1983) 0.84
Effects of pretreatment of mice with BCG cell walls in saline on subsequent vaccination with BCG oil droplet vaccine. Cell Immunol (1974) 0.84
An experimental model for immunotherapy of cancer. Natl Cancer Inst Monogr (1973) 0.84
Immunotherapy of cancer: tumor suppression and regression by cell walls of Mycobacterium phlei attached to oil droplets. J Natl Cancer Inst (1975) 0.84
Superiority of intravenously administered BCG and BCG cell walls in protecting rhesus monkeys (Macaca mulatta) against airborne tuberculosis. Z Immunitatsforsch Exp Klin Immunol (1972) 0.83
Effect of monophosphoryl lipid A on host resistance to bacterial infection. Infect Immun (1986) 0.82
Protective effect of muramyl dipeptide analogs in combination with trehalose dimycolate against aerogenic influenza virus and Mycobacterium tuberculosis infections in mice. J Biol Response Mod (1984) 0.82
Suppression of tumor growth and regression of established tumor with oil-attached mycobacterial fractions. Gan (1974) 0.82
Intralesional immunotherapy of malignant melanoma with mycobacterium smegmatis cell wall skeleton combined with trehalose dimycolate (P3). Cancer (1979) 0.82
Inhibition of pulmonary granuloma formation in mice by treatment with Mycobacterial protoplasm and immuno-suppressants and its relation to protection against aerosol infection with virulent Mycobacterium tuberculosis. Zentralbl Bakteriol Mikrobiol Hyg A (1981) 0.80
Glucan: attempts to demonstrate therapeutic activity against five syngeneic tumors in guinea pigs and mice. J Natl Cancer Inst (1978) 0.80
Chromatography of microbial lipids by centrifugation through microparticulate gel. J Bacteriol (1970) 0.79
Enhancement of chemiluminescence and phagocytic activities by nontoxic and toxic forms of lipid A. J Biol Response Mod (1986) 0.78
Enhancement of resistance of mice to tuberculosis by purified components of mycobacterial lipid fractions. J Infect Dis (1973) 0.77
Currents in tuberculosis research. J Infect Dis (1971) 0.77
Biology of the mycobacterioses. Structure and biological functions of mycobacteria. Ann N Y Acad Sci (1968) 0.77
Effects of nontoxic lipid A and endotoxin on resistance of mice to Toxoplasma gondii. J Biol Response Mod (1988) 0.77
Induction of resistance to tuberculosis in mice with defined components of Mycobacteria and with some unrelated materials. Zentralbl Bakteriol Mikrobiol Hyg A (1982) 0.76
Specific and nonspecific stimulation of resistance in mice aganist infection with Mycobacterium tuberculosis H37Rv. Pneumonologie (1970) 0.76
Determination of heptose in endotoxins. J Bacteriol (1966) 0.75
Occult endotoxin in bacterial protoplasm. J Bacteriol (1969) 0.75
Administration of BCG cell wall skeleton into malignant effusions: toxic and therapeutic effects. Cancer Treat Rep (1981) 0.75
Purification of 9 -tetrahydrocannabinol, an active constituent of marihuana, by accelerated microparticulate gel chromatography. Prep Biochem (1973) 0.75
Use of endotoxin and mycobacterial fractions in treating malignant epithelioma of the bovine eye. Proc Annu Meet U S Anim Health Assoc (1977) 0.75
Pressure accelerated chromatography through microparticulate silica columns packed by centrifugation. J Chromatogr Sci (1972) 0.75
Synergistic activity of components of mycobacteria and mutant Salmonella in causing regression of line-10 tumors in guinea pigs. Cancer Res (1979) 0.75
Immunotherapy of a guinea pig hepatoma with living BCG: a frozen liquid and a lyophilized preparation are equally active. Cancer (1977) 0.75
Preparation of an adjuvant-active, tuberculin-free peptidoglycolipid from human tubercle bacilli. Jpn J Microbiol (1974) 0.75
Efficacy of tumor cell extracts in immunotherapy of murine EL-4 leukemia. Cancer Res (1979) 0.75
[Immunotherapy with BCG and mycobacterial fractions and its use in bronchogenic carcinoma (author's transl)]. Prax Klin Pneumol (1979) 0.75
Solubility of endotoxin and stability of its biological activity in organic liquids. Biotechnol Bioeng (1969) 0.75
Mycobacterial cellular antigenic fractions. Am Rev Respir Dis (1965) 0.75
[Chemical structures and biological functions of mycobacterial cell walls with special reference to immunity against airborne infection by the strain M. tuberculosis H37Rv]. Bull Int Union Tuberc (1974) 0.75
A shortened synthesis of adjuvant dipeptide (MDP). Prep Biochem (1980) 0.75
Bacillus Calmette-Guérin cell wall immunotherapy of intramuscular and metastatic Morris rat hepatomas. Cancer Res (1978) 0.75
Preparation, purification and structure of endotoxin. J Okla State Med Assoc (1966) 0.75
Marihuana: identification of cannabinoids by centrifugal chromatography. Science (1971) 0.75
Intratumor chemoimmunotherapy with mitomycin C and components from mycobacteria in regression of line 10 tumors in guinea pigs. Cancer Res (1978) 0.75